Earnings ·
C4 Therapeutics reported second quarter 2026 financial results on August 11, 2026
CCCCC4 Therapeutics, Inc.
C4 Therapeutics reported second quarter 2026 financial results on August 11, 2026. Total revenue was $6.6 million, driven by a $20 million upfront payment from a new collaboration with Roche for degrader-antibody conjugate research. The company raised approximately $33.5 million in net proceeds through its at-the-market equity program. R&D expense decreased to $24.5 million and G&A expense fell to $8.6 million, resulting in a net loss of $23.6 million, or $0.18 per share. Cash, cash equivalents, and marketable securities totaled $300.4 million as of June 30, 2026, which management expects will fund operations through the end of 2028. The company operates in the biopharmaceutical industry, focusing on targeted protein degradation therapies for multiple myeloma.